---
document_datetime: 2023-09-21 18:25:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/neoclarityn-epar-procedural-steps-taken-authorisation_en.pdf
document_name: neoclarityn-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3662502
conversion_datetime: 2025-12-27 22:48:03.225642
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant SP Europe submitted on 7 September 1999 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Neoclarityn, through the centralised procedure. After agreement by the CPMP on 22 April 1999, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were:

Rapporteur:

Dr. Daniel Brasseur

Co-Rapporteur:

Prof. Hans Winkler

## Scientific advice

The  applicant  received  scientific  advice  from  the  CPMP  on  27  May  1998.  The  Scientific  Advice pertained to Part III and IV of the dossier.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 24 September 1999.
- The Rapporteur's first assessment report was circulated to all CPMP  Members on 3 December 1999.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP Members on 1 December 2000.
- During  the  meeting  on  18-20  January  2000  the  CPMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  applicant.  The  final  consolidated  list  of  questions  was  sent  to  the applicant on 24 January 2000.
- On 15 February 2000 the CPMP decided not to request an inspection of the manufacturing sites.
- The applicant submitted the responses to the consolidated list of questions on 15 June 2000.
- The Rapporteur circulated the Response Assessment Report on the applicant's responses to the List of Questions to all CPMP Members on 21 August 2000.
- During  the  meeting  on  19-21  September  2000  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Neoclarityn on 21 September 2000.